|
Cortecs is changing its name to Provalis and is to adopt a lower-risk strategy of funding its biotechnology research from its profitable businesses. 28-Oct-1999 Cortecs is looking to sell its food diagnostics, laboratory services and pharmaceutical sales companies, in order to reduce losses. 17-Mar-1999 Cortecs, the biotechnology company, has made 75 of its 270 staff redundant and its London and New York offices have been closed, as part of an ongoing cost-cutting campaign. 21-Jan-1999 Cortecs is to cut 70 jobs at its pharmaceuticals headquarters on Deeside. 08-Jan-1999 Cortecs has announced that Laphal Laboratories of France will distribute its Macritonin osteoporosis treatment. 16-Sep-1998 Cortecs is setting up a new company called Oratol in order to develop remedies for allergies and auto-immune diseases. 04-Jun-1998 Cortecs has agreed a £8m deal with Glaxo Wellcome for the marketing of its Macritonin osteoporosis drug in Greece, and is said to be in discussions with a number of other companies to licence the drug in other European countries. 18-May-1998 Cortecs has announced encouraging phase II trials for its Pseudostat chronic bronchitis vaccine, and hopes it will be ready for sale by 2000. 11-Mar-1998 Cortecs has obtained positive results from clinical tests for its Macritonin oral treatment for osteoporosis, and is already in discussions with large drug companies about distribution deals. 04-Feb-1998 Cortecs International has reported promising initial trial results for an oral form of insulin called Macrulin. 05-Nov-1997 Cortecs International has begun seeking approval for its first drug, the Macrotonin treatment for osteoporosis, in a number of European countries starting with Ireland and Finland. 12-Sep-1997 Cortecs has won a US patent for Flustat, its oral influenza vaccine. 19-Aug-1997 Cortecs has announced promising trial results for Macritonin, the osteoporosis treatment, and hopes to launch it on the market next year. 07-Aug-1997 Cortecs International, the biotechnology company, is moving its primary listing from Australia to London and creating a new holding company called Cortecs plc. 14-Jul-1997 Cortecs International is to launch oral calcitonin into Spain through a distribution deal with Ferrer Internacional. 16-Jan-1997 Cortecs International has launched Helisal One-Step, a new product that tests blood samples for the presence of the bacteria that causes gastritis and peptic ulcers. 31-Dec-1996 Cortecs International has launched Clotam, the anti-migraine drug, into the UK under licence from Bristol-Myers Squibb. 22-Oct-1996 Cortecs International has started trials of a bronchitis vaccine that is taken by mouth. 25-Jul-1996 Cortecs, the biotechnology company, has signed a deal with two Danish organisations - Osteometer Biotech and the Centre for Clinical and Basic Research - concerning clinical trials on oral methods of taking insulin. 25-Jun-1996 Cortecs International has raised £46m in an institutional share placing, and some of the proceeds will be used to show that its process that allows osteoporosis drugs to be taken orally can be adapted to work on other molecules. 05-Jun-1996 Cortecs International has won FDA clearance to market a diagnostic kit that detects the presence of a bug that causes peptic ulcers. 31-May-1996 Cortecs International has granted Teva Pharmaceuticals of Israel a licence to sell an oral formulation of salmon calcitonin, a drug for osteoporosis. 22-Mar-1996 Cortecs International has announced an agreement with Osteometer BioTech and the Centre for Clinical Basic Research, both of Denmark, to jointly develop an oral version of testosterone for male HRT. 23-Feb-1996
|